Patients who swtich from Pfizer’s (PFE) monster selling drug cholesterol pill Lipitor to Merck’s (MRK) Zocor, now available in generic form are more likely to have a heart attack or die.
According to Reuters: "The conclusion was that switching was associated with a 30 percent increase in the relative risk of major cardiovascular events, including heart attacks, strokes and death."
Of course, the study was back by Pfizer. Hard to say how it would have come out otherwise.
Douglas A. McIntyre
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.